|
KMID : 1130320170600020050
|
|
Korean Journal of Pediatrics
2017 Volume.60 No. 2 p.50 ~ p.54
|
|
|
Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures
|
|
Shin Jae-Won
Jung Yun-Seob
Park Kyung-Soo
Lee Soon-Min
Eun Ho-Seon
Park Min-Soo
Park Kook-In
Namgung Ran
|
|
|
Abstract
|
|
|
Purpose: The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM.
Methods: A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by a mean maintenance dose of 29 mg/kg/day.
Results: Seventeen neonates (94%) had seizure cessation within 1 week and 16 (84%) remained seizure-free at 30 days under the LEV therapy. The mean serum concentration of LEV was 8.7 μg/mL. Eight samples (5%) were found above the therapeutic range. No serious adverse effects were detected. In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.
Conclusion: LEV is a safe and effective option for the treatment of neonatal seizures with careful therapeutic drug monitoring.
|
|
|
KEYWORD
|
|
|
Levetiracetam, Neonatal seizure, Population pharmacokinetics, Safety, Pharmacokinetics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|